|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author | Experiment grup(n) | Control group(n) |  Treatments VS Control | Age of experiment group  | Age of control | Diagnosis | Diagnosis criteria | Experiment Events |  Control Events | Treatment Duration | jadad | Gender | Nation | Side Effect€ | Side Effect © | Assessment tool |
| Camilleri 2008 | 411 | 209 | PRU 2/4mg QD vs placebo | 48.0±14.3 | 48.9±13.0 | CIC | Rome III criteria | 269 | 76 | 12 weeks | 7 | mixed | USA | 326 | 149 | PAC-SYM score |
| Coremans 2003 | 27 | 26 | PRU 4mg QD vs placebo | 43.8±2.7 | 47.4±2.9 | CIC | Rome III criteria | 10 | 5 | 4 weeks | 5 | mixed | Beligium | 24 | 12 | constipation severity |
| Ke 2012 | 249 | 252 | PRU 2mg QD vs Placebo | 41.4±12.92 | 41.8±12.9 | CIC | Rome III criteria | 83 | 26 | 12 weeks | 5 | mixed | Asia-pacific | 142 | 92 | PAC-SYM score, PAC-QOL |
| Mueller-Lissner 2010 | 230 | 70 | PRU 1,2 or 4mg QD vs Placebo | 76.5±7.7 | 76±7.4 | CIC |  Rome III criteria | 81 | 12 | 4 weeks | 7 | mixed | Int | 104 | 32 | PAC-SYM score, PAC-QOL |
| Piessevaux 2015 | 177 | 169 | PRU 2mg QD vs Placebo | 49.4±15.8 | 48.3±16.3 | CIC | Rome III criteria | 76 | 59 | 24 weeks | 3 | mixed | Europe | 76 | 76 | PAC-SYM score, PAC-QOL |
| Quigley 2009 | 429 | 212 | PRU 2 OR 4 mg VS placebo | 48.9±13.9 | 46.2±13.0 | CIC | Rome III criteria | 193 | 59 | 12 weeks | 7 | mixed | USA | 264 | 92 | PAC-SYM socre, PAC-QOL |
| Tack 2008 | 473 | 240 | PRU 2 OR 4 mg VS placebo | 44.1±15.1 | 43.7±15.3 | CIC | Rome III criteria | 102 | 23 | 12 weeks | 7 | mixed | Int | 254 | 108 | PAC-SYM score, PAC-QOL |
| Emmanuel 2002 | 37 | 37 | PRU 1mg QD vs Placebo | NA | NA | CIC | symptoms criteria | 29 | 11 | 4 weeks | 5 | female | UK | 28 | 24 | HADS, SF-36 |
| Yiannnakou 2015 | 184 | 186 | PRU 2mg QD vs Placebo | 58.4±17.6 | 58.5±16.3 | CIC |  Rome III criteria | 86 | 57 | 12 weeks | 5 | male | Europe | 78 | 64 | PAC-SYM score, PAC-QOL |
| Fried 2007 | 158 | 164 | TEG 6mg BID vs Placebo | 51.1±17.1 | 51.8±17.2 | CIC |  Rome III criteria | 64 | 48 | 12 weeks | 7 | male | Int | 59 | 53 | Symptom Diary, BSFS |
| Kamm 2005 | 848 | 416 | TEG 6mg BID vs Placebo | 46.3±15.2 | 46.0±15.6 | CIC | Rome III criteria | 321 | 111 | 12 weeks | 5 | mixed | Int | 434 | 234 | Bristol Stool Form Scale, SF-36 |
| Barish 2010 | 119 | 118 | LUB 24μg Bid vs Placebo | NA | NA | CIC | Rome III criteria | 73 | 37 | 4 weeks | 5 | mixed | USA | 73 | 22 | Daily symptom Diary,SBM |
| Fukudo 2015 | 62 | 62 | LUB 24μg Bid vs Placebo | 42.7±16.4 | 41.5±14.2 | CIC | Rome III criteria | 47 | 18 | 4 weeks | 5 | mixed | Japan | 26 | 10 | Bristol Stool Form Scale, SF-36 |
| Johanson 2008 | 120 | 124 | LUB 24μg Bid vs Placebo | 48.0±12.3 | 49.1±12.9 | CIC | Rome III criteria | 68 | 45 | 4 weeks | 5 | mixed | USA | NA | NA | Daily symptom Diary,SBM |
| Lembo 2010 | 239 | 68 | LIN 75,150,300 or 600μg QD vs Placebo | 47.6±13.1 | 46.1±15.6 | CIC |  Rome III criteria | 161 | 24 | 4 weeks | 5 | mixed | USA | 81 | 22 | Daily symptom Diary,PAC-QOL |
| Lembo 2011(1) | 433 | 209 | LIN 145 or 290 mg, QD VS placebo | 47.4±14.2 | 49.3±14.3 | CIC | Rome criteria | 88 | 7 | 12 weeks | 7 | mixed | USA | 495/852 | 221/424 | Bristol Stool Form Scale, SF-36 |
| Lembo 2011(2) | 415 | 215 | LIN 145 or 290 mg, QD VS placebo | 47.2±12.8 | 47.0±13.5 | CIC | Rome criteria | 77 | 13 | 12 weeks | 7 | mixed | USA | NA | NA | Bristol Stool Form Scale, PAC-QOL |
| Lacy 2015 | 314 | 173 | LIN 145 or 290μg QD vs Placebo | 47.9 | 46.4 | CIC | Rome criteria | 156 | 47 | 12 weeks | 7 | mixed | USA | 151 | 65 | Bristol Stool Form Scale, Weekly IVRS |
| Kamm 2011 | 239 | 117 | BIS 10mg Qd VS Placebo | 55.8±15.9 | 54.7±15.1 | CIC | Rome III criteria | 190 | 58 | 4 weeks | 7 | mixed | UK | 178 | 45 | BSFS, Weekly IVRS  |
| S.KIENZLE-HORN 2006 | 27 | 27 | BIS 10mg Qd VS Placebo | 61.8±15.2 | 53.7±17.0 | constipation | Rome criteria | 19 | 14 | 5 day | 5 | mixed | Germany | 15 | 18 | SBMS，severity of symptoms |
| Dipalma 2007 | 204 | 100 | PEG 3350 17g vs placebo | 53.1±14.9 | 54.4±15.0 | constipation | Rome Criteria | 106 | 11 | 6 months | 7 | mixed | USA | 81 | 25 | IVRS |
| E Corazziari 2000 | 33 | 37 | PMF-100 17.5g vs placebo | 42.4±15.8 | 43.2±15.1 | constipation | Rome Criteria | 25 | 7 | 24 weeks | 7 | mixed | Italy | 22 | 17 | severity of symptoms |
| Cleveland 2001 | 23 | 23 | PEG 3350 17g vs placebo | ＞18 | ＞18 | constipation | symptoms criteria | 19 | 8 | 1 week | 6 | mixed | UK | NA | NA | Bowel movements, Severity of symptoms |
| Dipalma 2000 | 80 | 71 | PEG 3350 17g vs placebo | 46.7±14 | 45.8±13.1 | constipation | symptoms criteria | 54 | 33 | 2 weeks | 7 | mixed | USA | NA | NA | severity of symptoms |
| Bouhnik 2004 | 32 | 33 | PEG 4000 14-24g vs lactulose | 57±19 | 59±18 | constipation | Rome I Criteria | 26 | 27 | 4 Weeks | 7 | mixed | France | NA | NA | Daily Diary, Severity of symptoms |
| Candy 2006 | 28 | 30 | PEG+E 13.8g vs lactulose | 5.8 | 5.6 | constipation | symptoms criteria | 26 | 24 | 1 week | 7 | children | UK | 18 | 25 | Daily Diary, Severity of symptoms |
| Casparis 1968 | 54 | 49 | LAC 15-30ml Qd VS Placebo | NA | NA | Constipation | symptoms criteria | 47 | 30 | 3 weeks | 5 | NA | Netherland | NA | NA | The need for laxatives |
| Sanders 1978 | 19 | 23 | LAC 30ml Qd VS Placebo | 84.7 | 86.8 | Constipation | symptoms criteria | 16 | 12 | 8 weeks | 6 | mixed | USA | NA | NA | Severity of symptoms |
| Zhang Wei 2006 | 30 | 30 | ACU VS LAC 10ml Bid  | 65 | 67 | STC | AGAMPSD | 23 | 6 | 2 weeks | 7 | mixed | China | 0 | 0 | CCS, Colic Transit Time |
| Lin Rongzhi 2010 | 25 | 25 | ACU VS LAC 15ml Qd  | 20.68±2.27 | 21.24±1.45 | CFC | ROME III | 22 | 20 | 4 weeks | 7 | mixed | China | 0 | 0 | CCS, Colic Transit Time |
| Chen Lu 2010 | 57 | 31 | ACU VS LAC 15-30ml Bid  | 43.56±18.60 | 44.14±16.57 | CFC | Rome III | 36 | 18 | 4 weeks | 7 | mixed | China | 0 | 0 | CCS, Colic Transit Time |
| Su Shaoyun 2014 | 30 | 30 | ACU VS LAC 15ml Bid  | 42.13±2.01 | 39.10±1.88 | CFC | ROME III | 25 | 23 | 5 weeks | 6 | mixed | China | 0 | 0 | Symptoms Diary, PAC-QOL |
| Wang Jinmei 2016 | 57 | 73 | ACU VS LAC 10-30ml Qd | 73±5 | 74±6 | CFC | Chinese Guidline | 50 | 62 | 30 days | 5 | mixed | China | 0 | 0 | symptoms Diary |
| Jin Wenyu 2010 | 22 | 15 | ACU VS LAC 15-30ml Bid  | 39.14±14.45 | 45.13±17.09 | CFC | ROME III | 15 | 8 | 4 weeks | 5 | mixed | China | 0 | 0 | CCS |
| Peng Weina 2013 | 63 | 29 | ACU VS LAC 20-30ml Qd | 53±13 | 59±12 | CFC | ROME III | 41 | 14 | 4 weeks | 7 | mixed | China | 0 | 0 | SBMs |
| Chen 2013  | 14 | 16 | ACU vs SHAM ACU | 40±13 | 41±12 | constipation | NA | 13 | 10 | 8 weeks | 6 | female | China | 0 | 0 | Bristol Likert Scale |
| Liu 2016 | 536 | 539 | ACU vs ACU | 47.01±16.5 | 47.33±15.8 | CFC | Rome III | 185 | 70 | 20 weeks | 7 | mixed | China | 31 | 24 | bristol Likert Scale, PAC-QOL |
| Wang Chengwei 2010 | 48 | 24 | ACU vs SHAM ACU | 48.8±13.3 | 40.8±10.0 | CFC | Rome III | 37 | 14 | 4 weeks | 5 | mixed | China | 0 | 0 | Cleveland Clinic Score |
| Wu Jiani 2014 | 60 | 60 | ACU vs SHAM ACU | 49 | 52 | CFC | Rome III | 24 | 12 | 12 weeks | 7 | mixed | China | 0 | 0 | SBMs, Bristol Likert Scale |
| Peng Weina 2013 | 63 | 31 | ACU vs SHAM ACU | 53±13 | 52±17 | CFC | Rome III | 41 | 15 | 4 weeks | 7 | mixed | China | 0 | 0 | SBMs |